DOWNSIDE: The challenge is to grow its existing drugs. It will be interesting to see if Novartis and Mr. Graves can continue the success enjoyed with its current drug lineup-and whether Novartis will become a player in any moves to acquire Bristol-Myers Squibb Co., which could change Novartis' strategies greatly.
AD BUDGET: $1.16 billion
* Havas' Euro RSCG, N.Y.
* Interpublic's Deutsch, FCB, Gotham, Integrated Communications, McCann Erickson and Regan Campbell Ward-McCann, N.Y.
* Omnicom's Cline Davis & Mann and Merkley & Partners, N.Y.
* Publicis' LifeBrands and Saatchi & Saatchi, N.Y.
* WPP's CommonHealth, Parsippany, N.J.; Grey, MindShare, N.Y.